The following is excerpted from a January 9, 2012 article by Kris B. Mamula, Reporter for the Pittsburgh Business Times:
Takeda Pharmaceutical, Watson Pharmaceuticals and Andrx Labs have sued generic drugmaker Mylan Inc. for patent infringement in connection with its plans to market pioglitazone hydrochloride and extended release metformin hydrochloride tablets, Canonsburg-based Mylan announced Monday.
The two drugs are ingredients in Actoplus Met XR, which is prescribed to control blood glucose levels in adults with type 2 diabetes. Two common strengths of the drug had combined sales of approximately $21.4 million for the year ending Sept. 30, according to IMS Health, a Danbury Conn.-based trade group.
In a 10-count civil lawsuit filed Jan. 3, Takeda, Watson and Andrx allege Mylan's generic equivalent product infringes on patents that expire in 2016, 2021 and 2026.
Read the full article here.